Startups
Edit
https://revivethera.com/
Revive Therapeutics Ltd. CSE: RVV | USA: RVVTF
TrustedLast activity: 15.07.2026
Active
Focused on the research, development and commercialization of novel therapies and technologies for m
Overview
Location
Canada
Employees
1-10
Total raised
$246.92K
Founded date
2012
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 12
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 12, 2024 | Revive Therapeutics Provides Corporate Update | |
| Feb 26, 2024 | Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110 | NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQ... |
| Feb 26, 2024 | Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110 | |
| Jan 31, 2024 | Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500 | |
| Jan 31, 2024 | Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500 | NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQ... |
| Jan 24, 2024 | Revive Therapeutics Ltd. Announces Offering of Up to $3 Million | |
| Sep 28, 2022 | Covid-19 roundup: Shionogi’s antiviral pill hits the mark; Ocugen strikes deal for intranasal vaccine | Japanese pharma Shionogi’s Covid-19 antiviral against Omicron passed its Phase III trial in Asia, meeting its primary endpoint. The drug, a protease inhibitor known as ensitrelvir, was administered daily for five days and... |
| Jan 4, 2022 | Revive Therapeutics : RVV Deck January 2022a | A SPECIALTY LIFE SCIENCES COMPANY Corporate Presentation January 2022 OTCQB: FRANKFURT: RVVTF 31R Revive Therapeutics Ltd. | Office: 1-888-901-0036 | E-mail: [email protected] FORWARD LOOKING STATEMENTS Certain statements contained in ... |
| Jan 3, 2022 | Revive Therapeutics : RVV Deck January 2022 | A SPECIALTY LIFE SCIENCES COMPANY Corporate Presentation January 2022 OTCQB: FRANKFURT: RVVTF 31R Revive Therapeutics Ltd. | Office: 1-888-901-0036 | E-mail: [email protected] FORWARD LOOKING STATEMENTS Certain statements contained in ... |
Show more
Reviews 0
FAQ about Revive Therapeutics Ltd. CSE: RVV | USA: RVVTF
When was Revive Therapeutics Ltd. CSE: RVV | USA: RVVTF founded?
Revive Therapeutics Ltd. CSE: RVV | USA: RVVTF was founded in 2012.
How much funding has Revive Therapeutics Ltd. CSE: RVV | USA: RVVTF raised?
Revive Therapeutics Ltd. CSE: RVV | USA: RVVTF has raised $246.92K in total across 1 funding round.
What has the press written about Revive Therapeutics Ltd. CSE: RVV | USA: RVVTF?
Parsers VC has collected 12 articles mentioning Revive Therapeutics Ltd. CSE: RVV | USA: RVVTF, among them “Revive Therapeutics Provides Corporate Update” (Mar 12, 2024) and “Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110” (Feb 26, 2024).
Is Revive Therapeutics Ltd. CSE: RVV | USA: RVVTF still active?
Yes, Revive Therapeutics Ltd. CSE: RVV | USA: RVVTF is active; its latest activity on Parsers VC dates from Jul 15, 2026.